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Sir,
Vitiligo is a common, depigmenting disorder character-
ized by well-circumscribed cutaneous macules devoid of
melanocytes on the epidermis. Bone marrow transplan-
tation (BMT), which has significant therapeutic benefits
in haematologic disorders, such as leukaemia and
aplastic anaemia, provides convincing evidence for the
role of the immune system in some autoimmune diseases
(1). In this report we describe four patients with
haematologic malignancies in whom generalized vitiligo
developed after allogeneic BMT from siblings or
unrelated donor without depigmentary disorders.
CASE REPORTS
Patient no. 1
A 15-year-old Korean man was previously diagnosed as
having acute lymphocytic leukaemia (ALL) and received
a histocompatibility leukocyte antigen (HLA)-matched
allogeneic BMT from an unrelated donor after con-
ditioning with total body irradiation (TBI) and cyclo-
phosphamide. Neither the recipient nor the donor had a
history of depigmentary conditions. On the eighth day
after BMT, the patient was found to have acute graft-
versus-host disease (GVHD) presenting with generalized
cutaneous lesions and diarrhoea. GVHD was controlled
with cyclosporin A and corticosteroids. Three months
after BMT, he presented generalized well-circumscribed
white macules, which had a chalky white appearance
with Wood’s lamp. A skin biopsy specimen was taken
from one of the macules on the back and showed
complete disappearance of melanocytes. Narrowband
UVB therapy was given as monotherapy twice a week.
The starting dose was 280 mJ/cm2, with 15% dose
increments at each subsequent treatment. He achieved
w75% repigmentation with 26 treatments.
Patient no. 2
A 30-year-old Korean man with chronic myeloid
leukaemia received HLA-matched allogeneic BMT from
his sister after conditioning with TBI and cyclophosph-
amide. Neither the recipient nor the donor had a history
of depigmentary conditions. Ten days after BMT, the
patient developed acute GVHD with generalized cuta-
neous lesions, liver enzyme elevation and diarrhoea. He
was treated with a short course of methotrexate,
cyclosporin A, tacrolimus and corticosteroids. Two
years after BMT, he presented well-circumscribed white
macules on the whole body. A skin biopsy was
performed on the forearm and showed complete
disappearance of melanocytes. The patient refused any
treatment for the vitiligo.
Patient no. 3
A 28-year-old Korean man with ALL received HLA-
matched allogeneic BMT from his sister after condition-
ing with TBI and cyclophosphamide. Neither the
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recipient nor the donor had a history of depigmentary
conditions. With cyclosporin A and corticosteroids for
prophylaxis, he showed no sign of acute GVHD. He
suffered from progressive vitiligo on the whole body
from 26 months after BMT. Two months later, the
patient presented indurated, atrophic patches on the
forearms and palms, which was pathologically con-
firmed as sclerodermoid chronic GVHD. Liver biopsy
was performed due to the elevation of liver enzymes,
which revealed chronic GVHD. The patient was treated
with systemic and topical corticosteroids and showed
clinical improvement. However, the vitiligo lesions still
persisted and the patient refused further treatment.
Patient no. 4
A 43-year-old Korean man with myelodysplastic syn-
drome received HLA-matched allogeneic BMT from his
sister after conditioning with TBI, busulphan and
cyclophosphamide. There was no history of depigmen-
tary conditions. Methotrexate, cyclosporin A and
corticosteroids were administered as a prophylaxis for
acute GVHD. Three months after BMT, the patient
presented crusted, whitish patches on the lower lip, liver
enzyme elevation and gastrointestinal discomfort.
Biopsy specimens were obtained from the skin, liver
and gastric mucosa, all of which revealed chronic
GVHD. Two months later, although GVHD was
controlled with systemic corticosteroids, he showed
slowly progressive vitiligo on the face and upper
extremities, which presented a chalky white appearance
on Wood’s lamp examination. The patient was treated
with topical steroids and is planned to have narrowband
UVB therapy.
DISCUSSION
Allogeneic BMT is widely used in the treatment of
various haematologic disorders. The major complica-
tion of BMT is GVHD, which results from an
interaction between donor immunocompetent cells and
the recipient’s cells showing disparate antigens (1). BMT
is known to transfer autoimmune disease such as
autoimmune thyroiditis, immune cytopenia, insulin-
dependent diabetes, autoimmune polyendocrine failure
and vitiligo from donors to recipients with such diseases
(2, 3). Previous reports showed a high frequency of
various autoantibodies in long-term survivors after
allogeneic BMT. However, GVHD is known to be
associated with modulation of the host immune system
and could act as a triggering factor for the appearance
of autoimmune diseases such as vitiligo (4). Vitiligo is
not a common complication of GVHD or immuno-
suppression, and extensive leucoderma is only rarely
reported (5, 6). In our patients, two experienced acute
GVHD and two had chronic GVHD. In the former two
patients, time intervals between the onset of vitiligo and
acute GVHD were 3 and 48 months, respectively, and
the latter two patients showed 2- or 3-month intervals
between the onset of vitiligo and chronic GVHD. All
four patients showed progression of generalized vitiligo
even after achievement of improvement in GVHD with
immunosuppressive therapy. This suggests that GVHD,
especially chronic GVHD, might have a role in the
triggering of autoimmune-mediated vitiligo. The disease
progression tended to occur independently of GVHD
activity in our patients, which is similar to the previously
reported cases (7).
We conclude that GVHD might have a role in the
triggering of autoimmune-mediated vitiligo and this
observation adds new support for the role of auto-
immunity in the pathogenesis of some forms of vitiligo.
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